Principal investigator of the "Apoptosis, Immunity and Cancer" Group of the University of Zaragoza since 2014, a group that was created in 1995, just after my comeback from my two postdoctoral stays abroad. Within the group, I have led topics related on the one hand with the effector mechanisms of the immune system exerted by cytotoxic T lymphocytes (CTL) and NK cells and on the other with the regulation of the immune response, necessary to prevent autoimmune diseases. Both lines of research may have application in the improvement of cancer immunotherapy. As applications of those basic studies, we have generated liposomes decorated with the TRAIL death ligand and several granulysin-based immunotoxins, technologies that have been patented. One of those patents, related with an anti-CEA, granulysin-based immunotoxin, has been licensed to the spanish company Peaches Biotech. I have carried out numerous scientific collaborations and directed research projects of the Spanish Ministry of Science and Innovation/Economy and Competitiveness, of the Government of Aragon and I have also been coordinator of a Project funded by the European Union (2011-2013). I have been founder of the Spanish Network of Apoptosis (Apored) in 1997 and of the Spanish Immunotherapy Group (GEIT) in 2013. My research activity is combined with my teaching activity at the University of Zaragoza since 1995, having directed at this time 18 doctoral theses, plus another 2 that are in progress, and being 7 of them Extraordinary Doctoral Prize. In addition, I have been Coordinator of the Degree in Biotechnology at the University of Zaragoza from 2010 to 2015 and director of the Department to which I belong from 2015 to 2023. At this moment, I am the Coordinator of the Master in Tumor Immunology and Cancer Immunotherapy, that begun in 2002/23. Education and academic career. I have a degree in Organic Chemistry (1981-86) from the University of Zaragoza, where I did my doctoral thesis in the Department of Biochemistry (1986-90), under the direction of Andrés Piñeiro, on lipid metabolism during T lymphocyte activation. During the thesis I carried out several stays in the laboratory of José Uriel at the Institut de Recherches Scientifiques sur le Cancer in Villejuif, Paris. Subsequently, I made a first postdoctoral stay at the Medical Biology Institute, La Jolla, California (1991-93), under the supervision of Alan Kleinfeld and Matt Mescher, where I began to specialize in immunological issues and specifically in the activation mechanisms of CTL. I continued to focus on this direction in my second postdoctoral stay (1993-95), through a Marie Curie grant from the European Union at the Centre d'Immunologie de Marseille-Luminy, under the supervision of Anne-Marie Schmitt-Verhulst and Pierre Golstein, where I participated in pioneering studies on the Fas/Fas ligand system, of great relevance in the function of CTL and NK cells, as well as in the regulation of the immune response. In 1995 I returned to the University of Zaragoza, where I got a permanent position in 1999 and a chair in 2010. I have published a total of 149 research articles in journals indexed in the ISI, as well as 19 book chapters, being editor of a book on Tumor Immunology and Cancer Immunotherapy (2018). I have an H index of 43 by WoS and 53 by Google Scholar, being the 10th most cited author from my institution among the more than 3000 scientits from all fields. Number of doctoral thesis directed in the lsat 10 years: 9 thesis lectured and 2 in progress
Total publications in the first quartile(Q1): 110
h indez: 43 by WoS; 53 by Google Scholar
Total citacions: 12102 by WoS; 23139 by Google Scholar
Mean citations by paper: 69.95
10th most cited researcher in my institution among more than 3000 researchers from all fields by Google Scholar
Scientific chapters
- Generation of transmitochondrial cybrids in cancer cells. Soler-Agesta, Ruth; Ripollés-Yuba, Cristina; Marco-Brualla, Joaquín; Moreno-Loshuertos, Raquel; Sato, Ai; Beltrán-Visiedo, M.; Galluzzi, L.; Anel, Alberto. METHODS IN CELL BIOLOGY. ANIMAL MODELS OF DISEASE - PART B. 2024
PhD supervision
- Mecanismos efectores y de activación de linfocitos T citotóxicos y células NK. Universidad de Zaragoza. Sobresaliente "Cum Laude". 27/05/09
- Caracterización de anticuerpos contra ligandos de la familia del TNF. Papel de Apo3L/TWEAK en la regulación de la respuesta antitumoral de las celulas NK. Universidad de Zaragoza. Sobresaliente "Cum Laude". 14/07/06
- Mecanismos de regulación de la activación de los linfocitos T humanos. Universidad de Zaragoza. Sobresaliente "Cum Laude". 24/02/06
- Mecanismos citoliticos de los linfocitos T citotoxicos: perforina/granzimas, granulisina e inducción de fasl. Universidad de Zaragoza. Sobresaliente "Cum Laude". 04/12/03
- Caracterización de los mecanismos de apoptosis inducida por los fármacos antitumorales doxorrubicina y cladribina en leucemias humanas. Universidad de Zaragoza. Sobresaliente "Cum Laude". 28/03/03
- Mecanismos implicados en la regulación homeostática y en la resistencia a la apoptosis de células T humanas normales y tumorales. Universidad de Zaragoza. Sobresaliente "Cum Laude". 08/04/02
- Mecanismos de muerte celular programada inducidas por proteínas producidas por células del sistema inmunitario. Universidad de Zaragoza. Sobresaliente "Cum Laude". 19/06/98
UNIZAR teaching of the last six courses
|